Amyris (NASDAQ:AMRS): Baird lowered its price target on Amyris following its business update conference call. The firm cited the company’s comment it no longer expects to meet its production guidance and potential for lower margins given it will focus on value rather than volume. Shares are Neutral rated. The shares closed at $6.75, down $0.24 or 3.43% on the day. They have traded in a 52-week range of $6.85 to $33.85.
Chelsea Therapeutics (NASDAQ:CHTP): After Chelsea Therapeutics provided an update in the wake of the release of FDA briefing documents about its Northera drug, Leerink Swann believes that questions may be raised about the drug’s overall risk profile but the firm still thinks that the drug is safe overall. The firm maintains an Outperform rating on the shares. The shares closed at $3.10, down $1.89 or 37.88% on the day. They have traded in a 52-week range of $3.25 to $6.06.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com